146 related articles for article (PubMed ID: 33718897)
1. Cytomegalovirus-Specific Immunity Recovers More Slowly after Cord Blood Transplantation Compared with Matched Sibling Donor Allogeneic Transplantation.
Bejanyan N; Vlasova-St Louis I; Mohei H; Cao Q; El Jurdi N; Wagner JE; Miller JS; Brunstein CG
Transplant Cell Ther; 2021 Feb; 27(2):187.e1-187.e4. PubMed ID: 33718897
[TBL] [Abstract][Full Text] [Related]
2. Adaptive Natural Killer Cell and Killer Cell Immunoglobulin-Like Receptor-Expressing T Cell Responses are Induced by Cytomegalovirus and Are Associated with Protection against Cytomegalovirus Reactivation after Allogeneic Donor Hematopoietic Cell Transplantation.
Davis ZB; Cooley SA; Cichocki F; Felices M; Wangen R; Luo X; DeFor TE; Bryceson YT; Diamond DJ; Brunstein C; Blazar BR; Wagner JE; Weisdorf DJ; Horowitz A; Guethlein LA; Parham P; Verneris MR; Miller JS
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1653-62. PubMed ID: 26055301
[TBL] [Abstract][Full Text] [Related]
3. Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD.
Bejanyan N; Brunstein CG; Cao Q; Lazaryan A; Luo X; Curtsinger J; Mehta RS; Warlick E; Cooley SA; Blazar BR; Miller JS; Weisdorf D; Wagner JE; Verneris MR
Blood Adv; 2018 Apr; 2(8):909-922. PubMed ID: 29678809
[TBL] [Abstract][Full Text] [Related]
4. Single-unit unrelated cord blood transplantation versus HLA-matched sibling transplantation in adults with advanced myelodysplastic syndrome: A registry-based study from the adult MDS working group of the Japanese society for transplantation and cellular therapy.
Konuma T; Itonaga H; Shimomura Y; Fujioka M; Aoki K; Uchida N; Onizuka M; Jinguji A; Tanaka M; Ueda Y; Katayama Y; Sawa M; Tanaka H; Nakamae H; Kawakita T; Maruyama Y; Takahashi S; Ishimaru F; Kanda J; Ichinohe T; Atsuta Y
Hematol Oncol; 2024 Jan; 42(1):e3217. PubMed ID: 37592904
[TBL] [Abstract][Full Text] [Related]
5. Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy.
Szabolcs P; Mazor RD; Yackoubov D; Levy S; Stiff P; Rezvani A; Hanna R; Wagner J; Keating A; Lindemans CA; Karras N; McGuirk J; Hamerschlak N; López-Torija I; Sanz G; Valcarcel D; Horwitz ME
Transplant Cell Ther; 2023 Aug; 29(8):517.e1-517.e12. PubMed ID: 37120136
[TBL] [Abstract][Full Text] [Related]
6. Dendritic Cell Recovery Impacts Outcomes after Umbilical Cord Blood and Sibling Donor Transplantation for Hematologic Malignancies.
Touma W; Brunstein CG; Cao Q; Miller JS; Curtsinger J; Verneris MR; Bachanova V
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1925-1931. PubMed ID: 28729150
[TBL] [Abstract][Full Text] [Related]
7. Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors.
Majhail NS; Brunstein CG; Shanley R; Sandhu K; McClune B; Oran B; Warlick ED; Wagner JE; Weisdorf DJ
Bone Marrow Transplant; 2012 Apr; 47(4):494-8. PubMed ID: 21602900
[TBL] [Abstract][Full Text] [Related]
8. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
[TBL] [Abstract][Full Text] [Related]
9. Transfusion burden following reduced intensity allogeneic hematopoietic cell transplantation: Impact of donor type.
Subramanian S; Cohn C; DeFor T; Welbig J; Brunstein C; El Jurdi N; Weisdorf D
Transfusion; 2021 Jul; 61(7):2064-2074. PubMed ID: 33899243
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors.
Smith AR; Baker KS; Defor TE; Verneris MR; Wagner JE; Macmillan ML
Biol Blood Marrow Transplant; 2009 Sep; 15(9):1086-93. PubMed ID: 19660721
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines.
Aldenhoven M; Jones SA; Bonney D; Borrill RE; Coussons M; Mercer J; Bierings MB; Versluys B; van Hasselt PM; Wijburg FA; van der Ploeg AT; Wynn RF; Boelens JJ
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1106-9. PubMed ID: 25708213
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Adaptive NK Cells and CD8 T Cells by HLA-C Correlates with Allogeneic Hematopoietic Cell Transplantation and with Cytomegalovirus Reactivation.
Horowitz A; Guethlein LA; Nemat-Gorgani N; Norman PJ; Cooley S; Miller JS; Parham P
J Immunol; 2015 Nov; 195(9):4524-36. PubMed ID: 26416275
[TBL] [Abstract][Full Text] [Related]
13. Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cell-Depleted, CD34
Huang YT; Kim SJ; Lee YJ; Burack D; Nichols P; Maloy M; Perales MA; Giralt SA; Jakubowski AA; Papanicolaou GA
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1759-1766. PubMed ID: 28668490
[TBL] [Abstract][Full Text] [Related]
14. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
15. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
[TBL] [Abstract][Full Text] [Related]
16. Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.
Lazaryan A; Weisdorf DJ; DeFor T; Brunstein CG; MacMillan ML; Bejanyan N; Holtan S; Blazar BR; Wagner JE; Arora M
Biol Blood Marrow Transplant; 2016 Jan; 22(1):134-40. PubMed ID: 26365153
[TBL] [Abstract][Full Text] [Related]
17. Emergence of human CMV-induced NKG2C+ NK cells is associated with CD8+ T-cell recovery after allogeneic HCT.
van der Ploeg K; Sottile R; Kontopoulos T; Shaffer BC; Papanicolaou GA; Maloy MA; Cho C; Robinson KS; Perales MA; Le Luduec JB; Hsu KC
Blood Adv; 2023 Oct; 7(19):5784-5798. PubMed ID: 37196646
[TBL] [Abstract][Full Text] [Related]
18. Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.
Majhail NS; Brunstein CG; Tomblyn M; Thomas AJ; Miller JS; Arora M; Kaufman DS; Burns LJ; Slungaard A; McGlave PB; Wagner JE; Weisdorf DJ
Biol Blood Marrow Transplant; 2008 Mar; 14(3):282-9. PubMed ID: 18275894
[TBL] [Abstract][Full Text] [Related]
19. Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy.
de Witte MA; Sarhan D; Davis Z; Felices M; Vallera DA; Hinderlie P; Curtsinger J; Cooley S; Wagner J; Kuball J; Miller JS
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1152-1162. PubMed ID: 29505821
[TBL] [Abstract][Full Text] [Related]
20. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
